Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IBRX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Allogeneic Invariant Natural Killer T-ce | Community-Acquired Pneumonia (CAP) | Phase 3 · NCT07492875 | Withdrawn |
| BCG Vaccine | NMIBC | Phase 3 · NCT07551544 | Withdrawn |
| Nab-paclitaxel | Non Small Cell Lung Cancer | Phase 3 · NCT03520686 | Terminated |
| Cisplatin or Carboplatin | NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 3 · NCT07524257 | Withdrawn |
| Nogapendekin Alfa Inbakicept (N-803) | Non Small Cell Lung Cancer | Phase 3 · NCT03520686 | Terminated |
| Drug: Nogapendekin alfa inbakicept (NAI) | NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 3 · NCT07524257 | Withdrawn |
| Nab-paclitaxel (squamous) OR Pemetrexed | NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 3 · NCT07524257 | Withdrawn |
| Nab-paclitaxel OR Paclitaxel OR Docetaxe | NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 3 · NCT07524257 | Withdrawn |
| Prior failed checkpoint inhibitor | NSCLC Stage IV | Phase 3 · NCT06745908 | Recruiting |
| Fluorouracil | Pancreatic Cancer | Phase 2 · NCT04390399 | Active not recruiting |
| AAHI-SC2 Vaccine | COVID-19 | Phase 1/2 · NCT05370040 | Terminated |
| AAHI-SC3 Vaccine | COVID-19 | Phase 1/2 · NCT05370040 | Terminated |
| Aldoxorubicin HCl | Pancreatic Cancer | Phase 2 · NCT04390399 | Active not recruiting |
| Allogeneic invariant Natural Killer T (i | Acute Respiratory Distress Syndrome | Phase 2 · NCT07492888 | Withdrawn |
| Nogapendekin Alfa Inbakicept-Pmln | Long COVID | Phase 2 · NCT07123727 | Recruiting |
| Bacillus Calmette-Guérin (BCG) | Urothelial Carcinoma | Phase 1/2 · NCT03317158 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not IBRX's own candidates): Bevacizumab, Cisplatin, Docetaxel Anhydrous, Carboplatin, Pembrolizumab, Pemetrexed Disodium, Tislelizumab, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, Durvalumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IBRX holds $357.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $70.9M/quarter from operations, an estimated runway of 15.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 50 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IBRX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Patrick Soon-shiong Founder, Executive Chairman, Global Chie · +4.12M options |
Insider | 745,518,285 | 70.34% | 2026-07-31 |
| Blackrock Inc. | Institution (13F) | 34,083,262 | 3.22% | 2026-06-30 |
| State Street Corporation | Institution (13F) | 21,398,438 | 2.02% | 2026-06-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 17,863,911 | 1.69% | 2026-06-30 |
| Vanguard Capital Management LLC | Institution (13F) | 15,691,579 | 1.48% | 2026-06-30 |
| Shaw D.E. & Co., Inc. | Institution (13F) | 11,551,019 | 1.09% | 2026-06-30 |
| Two Sigma Investments, LP | Institution (13F) | 11,097,106 | 1.05% | 2026-06-30 |
| Geode Capital Management, LLC | Institution (13F) | 9,847,896 | 0.93% | 2026-06-30 |
| Millennium Management Llc | Institution (13F) | 5,579,793 | 0.53% | 2026-06-30 |
| Northern Trust Corporation | Institution (13F) | 3,565,248 | 0.34% | 2026-06-30 |
| Morgan Stanley | Institution (13F) | 3,432,678 | 0.32% | 2026-06-30 |
| Barry J. Simon Director · +174,391 options |
Insider | 2,802,788 | 0.26% | 2026-06-24 |
Share count 1,059,836,273 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-07-02 filed 2026-07-06 |
Cohen Cheryl |
Sale (S) | 131,210 | $9.50 | 125,386 |
| 2026-07-02 filed 2026-07-06 |
Cohen Cheryl |
Option exercise (M) | 55,979 | $2.98 | 256,596 |
| 2026-07-02 filed 2026-07-06 |
Cohen Cheryl |
Option exercise (M) | 55,979 | – | – |
| 2026-07-01 filed 2026-07-06 |
Selecky Christobel |
Option exercise (M) | 124,414 | – | – |
| 2026-07-01 filed 2026-07-06 |
Selecky Christobel |
Option exercise (M) | 35,064 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IBRX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →